Zealand Pharma A/S
OTC:ZLDPF

Watchlist Manager
Zealand Pharma A/S Logo
Zealand Pharma A/S
OTC:ZLDPF
Watchlist
Price: 59.56 USD 4.53%
Market Cap: 4.2B USD

EV/EBITDA
Enterprise Value to EBITDA

-12.8
Current
-18
Median
4.7
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-12.8
=
Enterprise Value
17.6B DKK
/
EBITDA
-1.4B DKK
EBITDA Growth EV/EBITDA to Growth
DK
Zealand Pharma A/S
OTC:ZLDPF
Average EV/EBITDA: 15.8
Negative Multiple: -12.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 316.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.3
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.4
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.8
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -578.4 N/A N/A
AU
CSL Ltd
ASX:CSL
17.3
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.8
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.3 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -687.8 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
31.1
2-Years Forward
EV/EBITDA
-405.1
3-Years Forward
EV/EBITDA
95.6